Pharma’s Manufacturing Reconfigurations Provide CDMOs with Expansion Opportunities

Why It Matters

The acquisitions expand CDMO capabilities while allowing pharma companies to streamline operations and mitigate supply‑chain risk, accelerating the industry’s move toward domestic manufacturing.

Key Takeaways

• Samsung Biologics gains first US site, adding 60,000 L capacity.
• Three pharma‑to‑CDMO facility sales occurred in one month, a sharp rise.
• Onshoring driven by tariff threats and $155 bn US investment plans.
• CDMOs expand networks, offering pharma flexible manufacturing footprints.
• GSK will source products from Samsung, reducing its in‑house footprint.

Pulse Analysis

The first quarter of 2026 saw an unprecedented flurry of pharma‑to‑CDMO facility transactions, a trend driven by mounting tariff threats and a strategic push to on‑shore production. Industry giants such as Roche, Novartis, Eli Lilly and Johnson & Johnson pledged $155 billion in U.S. manufacturing investments, creating a fertile environment for contract manufacturers to acquire existing sites rather than build from scratch. This shift not only shortens time‑to‑market but also aligns with regulatory encouragement for domestic drug supply resilience.

Samsung Biologics’ purchase of GSK’s Rockville plant marks a pivotal milestone, delivering its inaugural U.S. manufacturing presence and an additional 60,000 L of drug‑substance capacity—an 8% lift to its global portfolio. The site’s dual cGMP lines already support both clinical and commercial biologics, positioning Samsung to serve a broader contract base while retaining GSK as a key customer. Parallel deals, including Bristol Myers Squibb’s hand‑off to Rois and Sanofi’s transfer to Adragos, underscore a rapid consolidation of fill‑finish and sterile manufacturing capabilities within the CDMO sector.

For pharmaceutical companies, these divestitures translate into greater flexibility to reconfigure their domestic footprints, focusing internal resources on core R&D and pipeline development. CDMOs, meanwhile, gain scale, geographic diversification, and the ability to offer end‑to‑end services, strengthening their value proposition in an increasingly outsourced landscape. As the U.S. market continues to attract capital, the momentum of such acquisitions is likely to persist, reshaping the competitive dynamics between pharma innovators and contract manufacturers.